Assoc. Prof. SEÇİL DEMİRKOL CANLI

Personal Information

Email: secil.demirkol@hacettepe.edu.tr
Web: https://avesis.hacettepe.edu.tr/secil.demirkol

International Researcher IDs
ORCID: 0000-0003-0200-7962
Publons / Web Of Science ResearcherID: AAG-8038-2020
ScopusID: 57193957002
Yoksis Researcher ID: 284599

Biography

Dr. Seçil Demirkol Canlı

Dr. Seçil Demirkol graduated from the Department of Molecular Biology and Genetics at Bilkent University in 2012. She then gained her PhD degree in the same department under the supervision of Dr. Ali Osmay Güre in 2018. After a short post-doc in Güre lab, she joined Molecular Pathology Research and Application Center at Hacettepe University in May 2018. She is currently working as an Assist. Prof. at the Clinical Oncology Department of Cancer Institute. Her current research interests are molecular biomarkers of prognosis and treatment response in cancer.

https://www.researchgate.net/profile/Secil_Demirkol

https://www.linkedin.com/in/se%C3%A7il-demirkol-55069714b/r

Research interests

Cancer, prognosis, biomarker, response prediction, EMT

Education Information

Doctorate, Bilkent Üniversitesi, Fen Fakültesi, Moleküler Biyoloji Ve Genetik, Turkey 2012 - 2018
Undergraduate, Bilkent Üniversitesi, Fen Fakültesi, Moleküler Biyoloji Ve Genetik, Turkey 2008 - 2012

Certificates, Courses and Trainings

Health&Medicine, Anti-kanser potansiyelli bileşiklerin in vitro değerlendirilmesi, Institute for Biological Research, Belgrad Üniversitesi, Belgrad, Sırbistan, 2016
Health&Medicine, Kanser Biyolojisi için Biyoinformatik Metodlar, Hücre Ölümü Araştırma Derneği, İzmir, 2015
Health&Medicine, Deney Hayvanları Kullanımı, Molekuler Biology and Genetik Bölümü, Bilkent Universitesi, Ankara, 2014
Health&Medicine, Meme ve kolon kanser hücreleri için in vitro sferoid modellerinin oluşturulması, Department of Internal Medicine, Division of Oncology, Graz Medical University, Austria, 2013

Dissertations

Doctorate, Prediction of prognosis and chemosensitivity in gastrointestinal cancers, Bilkent Üniversitesi, Fen Fakültesi, Moleküler Biyoloji Ve Genetik, 2017

Research Areas

Bioinformatics, Molecular Biology and Genetics

Academic Titles / Tasks

Lecturer PhD, Hacettepe University, Rektörlük-B, Molecular Pathology Application and Research Center, 2018 - Continues

Research Assistant PhD, Ihsan Dogramaci Bilkent University, Faculty Of Science, Moleküler Biyoloji Ve Genetik, 2018 - 2018

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Glutamine withdrawal leads to the preferential activation of lipid metabolism in metastatic colorectal cancer**
Taskiran A. E. G., Karaoglu D. A., EYLEM C. C., Ermis C., Guederer I., NEMUTLU E., DEMİRKOL CANLI S., BANERJEE S.
TRANSLATIONAL ONCOLOGY, 2024 (SCI-Expanded)

II. **Breast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues**
Demirkol Canlı S.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol.25, no.11, pp.6054-6065, 2024 (SCI-Expanded)

III. **Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines.**
TÜRK S., Yanpar H., Baesmat A. S., Canli S., ÇINAR O. E., MALKAN Ü. Y., TÜRK C., HAZNEDAROĞLU İ. C., UÇAR G.
Heliyon, vol.9, no.9, 2023 (SCI-Expanded)

IV. **A Novel Gene List Identifies Tumors with a Stromal-Mesenchymal Phenotype and Worse Prognosis in Gastric Cancer**
Demirkol Canlı S., Üner M., Kucukkaraduman B., Karaoglu D. A., Isik A., Turhan N., Akyol A., Gomceli I., Gure A. O.
Cancers, vol.15, no.11, 2023 (SCI-Expanded)

V. **A positive feedback loop driven by fibronectin and IL-1β sustains the inflammatory microenvironment in breast cancer**
TUNALI G., Yanik H., ÖZTÜRK S. C., DEMİRKOL CANLI S., Efthymiou G., Yilmaz K. B., Van Obberghen-Schilling E., ESENDAĞLI G.
Breast cancer research : BCR, vol.25, no.1, pp.27, 2023 (SCI-Expanded)

VI. **Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma**
Karaoglu D. A., ÜNER M., ŞİMŞEK C., GÜRE A. O., DEMİRKOL CANLI S.
Biology, vol.12, no.2, 2023 (SCI-Expanded)

VII. **Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma**
Akgun H., METİNTAŞ S., AK G., Canlı S., Isbilen M., Gure A. O., METİNTAŞ M.
Archives of Medical Science, vol.19, no.2, pp.355-364, 2023 (SCI-Expanded)

VIII. **CSRP1 expression is associated with a mesenchymal, stroma-rich tumor profile and poor prognosis in colon cancer**
DEMİRKOL CANLI S.
Turkish Journal of Medical Sciences, vol.53, no.6, pp.1678-1689, 2023 (SCI-Expanded)

IX. **Gastric Carcinoma with Lymphoid Stroma: A Combination of Mismatch Repair Deficient Medullary Type and Epstein–Barr Virus-associated Gastric Carcinomas**
Üner M., Isık A., Oztop S., Karabulut E., Demirkol Canlı S., Akyol A.
International Journal of Surgical Pathology, vol.30, no.6, pp.623-633, 2022 (SCI-Expanded)

X. **Quality assurance: Evaluation and comparison of methods for electron microscopic measurement of GBM width and the effect of in-lab calibration in diagnostic renal pathology.**
Uner M., Demirkol Canlı S., Arend L. J.
Microscopy research and technique, vol.85, no.1, pp.290-295, 2022 (SCI-Expanded)

XI. **Dna methylation of pi3k/akt pathway-related genes predicts outcome in patients with pancreatic cancer: A comprehensive bioinformatics-based study**
Faleiro I., Roberto V. P., Canli S., Fraunhoffer N. A., Iovanna J., Gure A. O., Link W., Castelo-Branco P.
Cancers, vol.13, no.24, 2021 (SCI-Expanded)

XII. **Epithelial-to-Mesenchymal Transition Is Not a Major Modulating Factor in the Cytotoxic Response to Natural Products in Cancer Cell Lines.**
Kucukkaraduman B., Cicek E. G., Akbar M. W., Demirkol Canli S., Vural B., Gure A. O.
Molecules (Basel, Switzerland), vol.26, no.19, 2021 (SCI-Expanded)

XIII. **Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide**
Turk S., Turk C., Akbar M., Kucukkaraduman B., Isbilen M., Demirkol C., Malkan Ü. Y., Okay M., Ucar G., Sayinalp N., et al.
PLOS ONE, vol.15, no.11, 2020 (SCI-Expanded)

XIV. **Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.**
Demirkol C., Seza E., Sheraj I., Gömçeli I., Turhan N., Carberry S., Prehn J., Güre A., Banerjee S.
Carcinogenesis, vol.41, pp.1219-1228, 2020 (SCI-Expanded)

XV. **A novel 20-gene prognostic score in pancreatic adenocarcinoma**
Canli S., Dedeoglu E., Akbar M. W., Kucukkaraduman B., Isbilen M., Erdogan O. S., Erciyas S. K., YAZICI H., VURAL B., Gure A. O.
PLOS ONE, vol.15, no.4, 2020 (SCI-Expanded)

XVI. **A Sternness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer**
Akbar M. W., Isbilen M., Belder N., Canli S., Kucukkaraduman B., Turk C., Sahin O., Gure A. O.
JOURNAL OF CANCER, vol.11, no.4, pp.949-961, 2020 (SCI-Expanded)

XVII. **Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.**
TASKOPARAN B., SEZA E., Demirkol S., TUNCER S., STEFEK M., GURE A., BANERJEE S.
Cellular oncology (Dordrecht), vol.40, pp.563-578, 2017 (SCI-Expanded)

XVIII. **A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer.**
Demirkol S., GOMCELI I., ISBILEN M., DAYANC B., TEZ M., BOSTANCI E. Ö., TURHAN N., AKOGLU M., OZYERLI E., DURDU S., et al.
Journal of Cancer, vol.8, pp.1113-1122, 2017 (SCI-Expanded)

Articles Published in Other Journals

I. **Claudin 18.2 Expression in Gastric Adenocarcinomas in a Large Turkish Cohort**
Işık A., GÜNER G., Zeyneloğlu C., DEMİRKOL CANLI S., TAŞTAN H., AKYOL A.
Abant Tıp Dergisi, vol.12, no.2, pp.122-130, 2023 (Peer-Reviewed Journal)

II. **Evaluation of Prognostic Markers in Cancer-associated Fibroblast Based Sub-groups of Colorectal Cancer**
Demirkol Canlı S.

Acta Medica, vol.53, no.2, pp.133-143, 2022 (Peer-Reviewed Journal)

Books & Book Chapters

I. **Uygulamaya Yönelik Genetik Bilimci Gözüyle Kanserde Gelecek Öngörüleri**
Demirkol Canlı S., Güre A. O., Akçay A. G., Akbar M. W.
in: Kanser Moleküler Biylojisi, Baran Y, Editor, Hipokrat Yayınevi, Ankara, pp.519-529, 2018

Supported Projects

TÜRK S., TÜRK C., UÇAR G., DEMİRKOL CANLI S., HAZNEDAROĞLU İ. C., Project Supported by Higher Education Institutions, Stafilokokal enterotoksinler SEA ve SEB varlığında Akut miyeloid lösemi (AML) hücre hatlarının ilaç yanıtı profilinin ve kemoterapiye yanıtının belirlenmesi, 2019 - 2021

Memberships / Tasks in Scientific Organizations

MOKAD (Moleküler Kanser Araştırma Derneği), Member, 2019 - Continues
Türkiye Moleküler Biyoloji Derneği, Member, 2018 - Continues

Metrics

Publication: 21
Citation (WoS): 106
Citation (Scopus): 110
H-Index (WoS): 6
H-Index (Scopus): 6

Scholarships

TUBITAK-2211 Yurt içi lisansüstü burs programı, TUBITAK, 2012 - 2017
Kapsamlı Burs, University, 2008 - 2012
TUBITAK-2205 Yurt içi lisans burs programı, TUBITAK, 2008 - 2012

Awards

DEMİRKOL CANLI S., 2018 Doktora Başarı Ödülü, Türkiye Moleküler Biyoloji Derneği, September 2018